| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MNPR | Common Stock | Options Exercise | +2.86K | +16% | 20.7K | Dec 31, 2022 | Direct | F1 | ||
| holding | MNPR | Common Stock | 3.06M | Dec 31, 2022 | See Footnote | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MNPR | Restricted Stock Units | Options Exercise | $0 | -2.86K | -100% | $0.00* | 0 | Dec 31, 2022 | Common Stock | 2.86K | Direct | F1, F3 |
| Id | Content |
|---|---|
| F1 | Represents shares acquired on vesting and settlement of restricted stock units. |
| F2 | This is based upon the 3,055,394.12 shares of Monopar common stock that Gem Pharmaceuticals, LLC, indirectly controls through TacticGem LLC. As a manager of Gem Pharmaceuticals, LLC, Mr. Klausner may be deemed to share voting and dispositive power over these 3,055,394.12 shares. Mr. Klausner disclaims beneficial ownership of the 3,055,394.12 shares held by Gem Pharmaceuticals, LLC, except to the extent of his pecuniary interest therein. |
| F3 | On February 2, 2022, the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. |